ReviewPharmacological reviews2018
Mechanisms and Drug Development in Atrial Fibrillation.
Review in Pharmacological reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis of colchicine in prevention of atrial fibrillation following cardiothoracic surgery or cardiac intervention.Journal of cardiothoracic surgery · 2022Pooled it
- Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation.Cardiovascular research · 2026Article
- High-power short-duration vs conventional radiofrequency ablation for atrial fibrillation in patients over 80 years of age: A propensity-score matched cohort analysis.Heart rhythm O2 · 2025Article
- SNAP25-dependent membrane trafficking of the Kv1.5 channel regulates the onset of atrial fibrillation.Nature communications · 2025Article
- Rational design, synthesis, and evaluation of novel polypharmacological compounds targeting NaThe Journal of biological chemistry · 2025Article
- mScience China. Life sciences · 2025Article
- The Influence of Empagliflozin on the Expression of Mitochondrial Regulatory Proteins in Human Myocardium in an Ex Vivo Model of Short-Term Atrial Tachypacing.International journal of molecular sciences · 2025Article
- The Electroanatomic Volume of the Left Atrium as a Determinant of Recurrences in Patients with Atrial Fibrillation After Pulmonary Vein Isolation: A Prospective Study.Biomedicines · 2024Article
- The predictive value of monocyte count to high-density lipoprotein cholesterol ratio combined with left atrial diameter for post-radiofrequency ablation recurrence of paroxysmal atrial fibrillation in patients.Journal of cardiothoracic surgery · 2024Article
- Clinical usefulness of digital twin guided virtual amiodarone test in patients with atrial fibrillation ablation.NPJ digital medicine · 2024Article
- A Comparison of the Impact of Pharmacological Treatments on Cardioversion, Rate Control, and Mortality in Data-Driven Atrial Fibrillation Phenotypes in Critical Care.Bioengineering (Basel, Switzerland) · 2024Article
- Therapeutic advances in atrial fibrillation based on animal models.Journal of Zhejiang University. Science. B · 2024Review
- Knowledge, attitude, and practice of atrial fibrillation in high altitude areas.Frontiers in public health · 2024Article
- Association between aspirin and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study based on mimic-IV database.Frontiers in cardiovascular medicine · 2024Article
- Role of RIPK3‑CaMKII‑mPTP signaling pathway‑mediated necroptosis in cardiovascular diseases (Review).International journal of molecular medicine · 2023Review
- Advances in basic and translational research in atrial fibrillation.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation.International journal of molecular sciences · 2023Review
- Research on atrial fibrillation mechanisms and prediction of therapeutic prospects: focus on the autonomic nervous system upstream pathways.Frontiers in cardiovascular medicine · 2023Review
- Involvement of plasminogen activator inhibitor-1 in p300/p53-mediated age-related atrial fibrosis.PeerJ · 2023Article
- Bioengineered peptibodies as blockers of ion channels.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Atrial fibrillation is a highly prevalent cardiac arrhythmia and the most important cause of embolic stroke. Although genetic studies have identified an increasing assembly of AF-related genes, the impact of these genetic discoveries is yet to be realized. In addition, despite more than a century of research and speculation, the molecular and cellular mechanisms underlying AF have not been established, and therapy for AF, particularly persistent AF, remains suboptimal. Current antiarrhythmic drugs are associated with a significant rate of adverse events, particularly proarrhythmia, which may explain why many highly symptomatic AF patients are not receiving any rhythm control therapy. This review focuses on recent advances in AF research, including its epidemiology, genetics, and pathophysiological mechanisms. We then discuss the status of antiarrhythmic drug therapy for AF today, reviewing molecular mechanisms, and the possible clinical use of some of the new atrial-selective antifibrillatory agents, as well as drugs that target atrial remodeling, inflammation and fibrosis, which are being tested as upstream therapies to prevent AF perpetuation. Altogether, the objective is to highlight the magnitude and endemic dimension of AF, which requires a significant effort to develop new and effective antiarrhythmic drugs, but also improve AF prevention and treatment of risk factors that are associated with AF complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.